Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses

Wnt/β-catenin inhibition disrupts drug-tolerance in isogenic carboplatin-resistant models of Triple-Negative Breast Cancer

Molecular stratification within triple-negative breast cancer

Long Non-Coding RNAs in Triple-Negative Breast Cancer

Cancers, Free Full-Text

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial

Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer, Experimental Hematology & Oncology

Frontiers Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer

Long Non-Coding RNAs in Triple-Negative Breast Cancer

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors [PeerJ]

Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression

Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer - ScienceDirect